

Erratum to: Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)

Mario Scartozzi¹ · Loic Vincent² · Marielle Chiron³ · Stefano Cascinu⁴

Published online: 20 December 2016
© Springer International Publishing Switzerland 2016

Erratum to: Targ Oncol (2016) 11:489–500
DOI 10.1007/s11523-016-0447-4

The original version of this article unfortunately contains a mistake.

Page 494, Table 2, ‘Characteristic’ section, ‘Additional eligibility criteria’ subsection, ‘1st line early progressors (1 L PFS < 3 month)’ row: The cell entry in the ‘Raise’ column, which previously read:

“X”

should read:

“✓”

The online version of the original article can be found at <http://dx.doi.org/10.1007/s11523-016-0447-4>.

✉ Mario Scartozzi
marioscartozzi@gmail.com

¹ Medical Oncology, University Hospital and University of Cagliari, Pole University Hospital, BDUilio Casula[^] - S.S. 554, Km 4,500 Bivio per Sestu, 09042 Monserrato, CA, Italy

² Sanofi Oncology External Innovation, Vitry-sur-Seine, France

³ Sanofi Oncology Translational Medicine, Vitry-sur-Seine, France

⁴ Medical Oncology, University Hospital and University of Modena and Reggio Emilia, Modena, Italy